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chronic, relapsing inflammatory disorder associated with an
elevated risk of colorectal cancer (CRC). IBD-associated CRC
(IBD-CRC) may represent a distinct pathway of tumorigenesis
compared to sporadic CRC (sCRC). Our aim was to compre-
hensively characterize IBD-associated tumorigenesis inte-
grating multiple high-throughput approaches, and to compare
the results with in-house data sets from sCRCs. METHODS:
Whole-genome sequencing, single nucleotide polymorphismarrays, RNA sequencing, genome-wide methylation analysis,
and immunohistochemistry were performed using fresh-frozen
and formalin-fixed tissue samples of tumor and corresponding
normal tissues from 31 patients with IBD-CRC. RESULTS:
Transcriptome-based tumor subtyping revealed the complete
absence of canonical epithelial tumor subtype associated with
WNT signaling in IBD-CRCs, dominated instead by mesen-
chymal stroma-rich subtype. Negative WNT regulators AXIN2
and RNF43 were strongly down-regulated in IBD-CRCs and
chromosomal gains at HNF4A, a negative regulator of WNT-
induced epithelial–mesenchymal transition (EMT), were less
frequent compared to sCRCs. Enrichment of hypomethylation at
HNF4a binding sites was detected solely in sCRC genomes.
WHAT YOU NEED TO KNOW
BACKGROUND AND CONTEXT
Inflammatory bowel disease increases the risk of
colorectal cancer and the tumors developing in patients
may be genetically and epigenetically distinct compared
to sporadic tumors.
NEW FINDINGS
Transcriptomic analyses of colorectal cancer specimens
from patients with inflammatory bowel disease revealed
August 2021 Inflammatory Bowel Disease and Colon Cancer 593PIGR and OSMR involved in mucosal immunity were dysregu-
lated via epigenetic modifications in IBD-CRCs. Genome-wide
analysis showed significant enrichment of noncoding mutations
to 50untranslated region of TP53 in IBD-CRCs. As reported
previously, somatic mutations in APC and KRAS were less
frequent in IBD-CRCs compared to sCRCs. CONCLUSIONS:
Distinct mechanisms of WNT pathway dysregulation skew IBD-
CRCs toward mesenchymal tumor subtype, which may affect
prognosis and treatment options. Increased OSMR signaling
may favor the establishment of mesenchymal tumors in pa-
tients with IBD.the absence of canonical epithelial tumor subtype and
predominance of mesenchymal tumors associated with
oncostatin M receptor overexpression.
LIMITATIONS
The intensive surveillance of colorectal cancer in patients
with inflammatory bowel disease makes these tumors
rare, limiting the sample size of the study.
IMPACTKeywords: Colorectal Cancer; Inflammatory Bowel Disease;
Epithelial–Mesenchymal Transition; DNA Methylation;
Consensus Molecular Subtype.
nflammatory bowel disease (IBD), comprising ulcera-The results suggest that colon inflammation may favor the
development of mesenchymal tumor subtype, which has
previously been associated with poor survival in large
colorectal cancer cohorts.
*Authors share co-first authorship.
Abbreviations used in this paper: AI, allelic imbalance; CD, Crohn’s dis-
ease; CMS, consensus molecular subtype; CRC, colorectal cancer; DE,
differentially expressed; DML, differentially methylated loci; EMT, epithe-
lial-mesenchymal transition; FDR, false discovery rate; IBD, inflammatory
bowel disease; IBD-CRC, inflammatory bowel disease–associated colo-
rectal cancer; MSI, microsatellite instability; MSS, microsatellite stable;
SBS, single base substitution; sCRC, sporadic CRC; SV, structural variant;
TGF-b, transforming growth factor b; TSS, transcription start site; UC,
ulcerative colitis; UTR, untranslated region; WGS, whole-genome
sequencing.
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ATItive colitis (UC) and Crohn’s disease (CD), involves a
complex interplay of genetic predisposition and environ-
mental factors that alter host–microbiota interactions
causing dysregulation of gut immune responses.1 The
growing prevalence and diminishing age at onset of IBD
amplify the risk of comorbidities and the associated eco-
nomic burden.2 Patients with IBD have an elevated risk of
colorectal cancer (CRC)3 attributed to chronic inflammation,
yet the detailed mechanisms remain elusive.4
Accumulating evidence suggests that IBD-associated CRC
(IBD-CRC) may emerge through a distinct pathway of
tumorigenesis compared to sporadic CRC (sCRC). Patients
with IBD are younger at CRC diagnosis and the tumors
develop at inflamed areas of the colon with characteristic
clinicopathologic features.4,5 IBD-CRCs show lower fre-
quency of somatic APC and KRAS mutations, whereas TP53
mutations occur earlier in tumorigenesis compared to
sCRCs.4,6–10 Despite reduced APC mutations, nuclear accu-
mulation of b-catenin is prevalent in IBD-CRCs,11 suggesting
an alternative mechanism of WNT pathway activation.
Additional suggested driver genes have varied across stud-
ies,6–10 while the frequency of hypermutated9 and micro-
satellite unstable tumors,12 level of somatic copy number
alterations,9,10 and distribution of somatic mutational sig-
natures6,9,10 appear similar to sCRCs. Studies on DNA
methylation patterns characterizing IBD-CRC have focused
on a limited number of genes13–15 or microarray data,16
warranting further genome-wide analyses.
Transcriptome-based classification of CRCs has emerged
as a powerful tool to describe tumor transcriptional, genetic,
epigenetic, and microenvironment characteristics.17,18 A
large-scale international effort resulted in amalgamation of
4 consensus molecular subtypes (CMSs).17 CMS distribution
remains unknown in IBD-CRC; in sCRC, epithelial WNT-
associated CMS2 is the most common and mesenchymal
CMS4 associates with poor prognosis.17
Here, we integrate multiple high-throughput sequencing
approaches to comprehensively characterize IBD-CRC and
to identify differences compared to sCRC. Our most striking
finding was the complete absence of CMS2 tumors among
IBD-CRCs that were instead skewed toward CMS4.Materials and Methods
Samples
The study adhered to the Declaration of Helsinki and was
approved by the local ethics committee (details are in
Supplementary Material). CRC patient samples were collected
in 1994–2017 at 9 regional hospitals in Finland.19–21 Thirty-
one IBD-CRC cases were identified from our collection
comprising approximately 2,500 CRC patients (UC: n ¼ 27, CD:
n ¼ 2, unclassified IBD: n ¼ 2 sharing features of UC and CD)
(Table 1). The availability of sample material for downstream
analyses is summarized in Supplementary Figure 1.
Whole-Genome Sequencing
DNA was isolated from fresh-frozen tumor, normal colon, or
blood of 29 patients with IBD-CRC. Libraries were prepared
using TruSeq Nano DNA HT or TruSeq PCR-Free Kit (Illumina),
followed by paired-end sequencing using Illumina platform
(HiSeqXTen/HiSeq2000). sCRCs were sequenced as described
previously.22














c174.1T F UC 38 54 Cecum AC I 2 MSS
c175.1T M UC 33 48 Rectum AC II 3 MSS
c269.1T F UC 41 41 Cecum ACPM II 2 MSS
c3.1T M IBD-U 27 48 Transverse colon AC II 1 MSS
c424.1T1 M UC 61 72 Rectosigmoid junction AC III 3 MSS
c461.1T M UC 82 82 Ascending colon ACPM III 3 MSS
c492.1T M UC 57 57 Rectum AC III 2-3 MSS
c589.1T F UC 43 50 Transverse colon AC III 1 MSS
c596.1T M UC 25 51 Rectum AC II 2 MSS
c696.1T F UC 19 42 Cecum AC III 3 MSS
c745.1T M CD 25 55 Rectum AC II 2 MSS
c989.1T F UC 26 62 Cecum AC III 3 MSS
s1111.1T M UC 36 64 Rectum AC II 1 MSS
s1138.1T M UC 41 61 Rectum AC II 2 MSS
s1170.1T M UC 65 65 Sigmoid colon AC III NA MSS
s1179.1T M UC 15 50 Transverse colon ACPM III 2 MSS
s205.1T M UC 22 60 Descending colon AC II 2 MSS
s576.1T M UC 22 41 Ascending colon AC III 3 NA
s617.1T M UC 20 33 Rectum ACM IV NA MSS
s649.1T M UC 20 33 Cecum ACM III NA MSS
s660.1T F IBD-U 56 66 Ascending colon AC II 2 MSI
s683.1T M UC 8 46 Cecum ACM II NA MSS
s700.1T M UC 41 64 Transverse colon AC I 1 MSS
s703.1T F UC 11 22 Descending colon ACPM III 2 MSS
s750.1T F UC 13 30 Cecum ACPM III 3 MSS
s751.1T M UC 61 61 Sigmoid colon AC III 3 MSS
s763.1T M CD 18 44 Rectum AC I 3 MSS
s814.1T F UC 42 72 Rectum ACPM I 3 MSS
s842.1T F UC 16 53 Rectum ACPM III 3 MSS
s85.1T M UC 64 64 Cecum AC I NA MSS
s982.1T1b,c M UC 34 34 Cecum ACPM III 2 MSI
s982.1T2b,c M UC 34 34 Splenic flexure ACPM III 2 MSI
AC, adenocarcinoma; ACM, mucinous adenocarcinoma; ACPM, partially mucinous adenocarcinoma; IBD-U, unclassified IBD;
NA, not available.
aIn cases where IBD was diagnosed together with CRC based on pathologic findings from the surgical resection, there was
often a history of several years of undiagnosed gastrointestinal symptoms mentioned in the clinical data.
bTwo tumors sampled from the same individual.
cThe individual was also diagnosed with hereditary nonpolyposis CRC.




ATSomatic Variant Calling and Analysis
Sequence alignment to GRCh38 reference genome, other
data preprocessing steps, and somatic variant calling wereperformed with GenomeAnalysisToolkit GATK4 best practices
workflow (version 4.0.4.0.) for all tumor/normal pairs. Gene
annotation (Ensembl genes release 89) for somatic single













ATnucleotide variants and small insertions/deletions was per-
formed with BasePlayer.23
Mutational Signatures
Somatic mutational signatures were extracted from whole-
genome sequencing (WGS) data of 237 colorectal tumor/
normal pairs, including the 27 paired IBD-CRCs. Briefly, single
base substitutions (SBSs) were classified based on their flank-
ing sequence context (±1 bp) into 96 possible mutation types.
These mutational spectra were analyzed with standard non-
negative matrix factorization, as described previously.22,24
OncodriveFML
OncodriveFML (version 2.2.0)25 was used to analyze the
coding sequence, 30untranslated region (UTR), and 50UTR for
signals of positive selection using the somatic mutations from
27 microsatellite stable (MSS) IBD-CRCs.
Allelic Imbalance
Single nucleotide polymorphism array data were analyzed
previously from 1699 colorectal tumor/normal pairs,26
including 23 IBD-CRCs; allelic imbalance (AI) regions of so-
matic allelic loss and gain were processed with the same
pipeline.26 Variant calls (HaplotypeCaller) from WGS data were
used to calculate AI for 6 additional IBD-CRCs lacking single
nucleotide polymorphism array data. The presence of AI in each
tumor was evaluated at loci found heterozygous in the corre-
sponding normal sample, as described previously.26 Analysis
was limited to MSS IBD-CRCs (n ¼ 27) and MSS sCRCs (n ¼
1360; microsatellite instability [MSI] statuses from Palin
et al26).
RNA Sequencing
Trizol-extracted RNA from 64 CRCs, including 17 IBD-CRCs,
underwent HiSeq LncRNA-Seq library preparation and paired-
end sequencing using Illumina HiSeqXTen. Raw sequences
were mapped onto the human transcriptome (ensembl release
79) using Salmon (version 0.12.0).27 Gene-level quantification
was done with DESeq2 (version 1.18.1),28 followed by limma
(version 3.34.9)29 correction of sequencing batch effects.
Differential Expression Analysis
Differential gene expression was analyzed using Partek
Genomics Suite 6.6 (Partek Inc) Gene Expression workflow,
followed by pathway analysis using PANTHER (version 15.0).30
Consensus Molecular Subtypes
Random forest classifier of CMSClassifier R package17 was
used to call CMS for each RNA-sequenced tumor, expressed
here as the nearest CMS (RF.1) predicted by the classifier.Deconvolution
The proportions of tumor-infiltrating immune cells were
estimated from RNA sequencing data using CIBERSORT.31,32
Reference was created as described previously33 by
combining bulk RNA sequencing data from isolated blood
immune cells (accession GSE60424) and representativemedian expression profiles from CRCs and normal colon
samples from an independent data set.34 See Supplementary
Table 16.
Cell type–specific gene expression profiles were inferred
from RNA sequencing data using PRISM,35 combining single-
cell RNA sequencing data of healthy colon36 and CRCs37 as
reference.
Immune Cell Score
Whole-section slides from 265 formalin-fixed, paraffin-
embedded CRCs, including 26 IBD-CRCs, were stained with
anti-CD3 (LN10, 1:200; Novocastra) and anti-CD8 (SP16,
1:400; Thermo Scientific) antibodies. Positively stained cells
were analyzed using QuPath,38 as described previously.39
The immune cell score was formulated as described previ-
ously,40 following the original method by Galon et al.41
Nanopore Long-Read Sequencing
Libraries were prepared for 20 IBD-CRCs, 36 sCRCs, and
12 normal colon samples from IBD-CRC patients following
Genomic DNA by Ligation (SQK-LSK109) protocol (Oxford
Nanopore Technologies). Sequencing and base-calling on
PromethION platform employed Live base-calling with
MinKNOW. Reads were aligned against the reference
genome GRCh38 using minimap2 (version 2.16; preset:
map-ont).42 Structural variants (SVs) were identified using
Sniffles (version 1.0.11)43 and merged together from all
tumors and normals with SURVIVOR (version 1.0.6)44 to
filter out SVs found in any normal sample. Genome-wide
methylation patterns were obtained using Nanopolish.45
Differentially methylated loci (DMLs) at autosomal regions
were identified and analyzed with R, version 3.5.1 using R
packages DSS (version 2.28.0,)46 bsseq (version 1.16.1),
annotatr (version 1.12.1),47 and Locus Overlap Analysis
(version 1.16.0).48 Chromatin immunoprecipitation
sequencing and DNase-sequencing data and 15 chromatin
states provided by Roadmap Epigenomics49 project
(Supplementary Table 12) and transcription factor binding
sites from CRC cell lines50 served as region set databases in
Locus Overlap Analysis.
Data Availability
Genome-wide somatic single nucleotide variant and
insertion/deletion calls (GRCh38) are deposited in the EGA
database under accession code EGAS00001004710.Results
Somatic Point Mutations in Known Colorectal
Cancer Driver Genes and Immunity-Related
Genes Characterize Inflammatory Bowel
Disease–Associated Colorectal Cancers
The study comprised 31 cases of IBD-CRC (Table 1); 29
underwent WGS. A total of 1,104,175 somatic single nucle-
otide variants and insertion/deletions were identified
(Supplementary Figure 2). Two outliers with high somatic
variant counts were explained by MSI, a distinct pathway of




ATCRC tumorigenesis driven by mismatch repair deficiency.
We focused on the more typical MSS IBD-CRCs.
The 27 MSS IBD-CRCs harbored a median of 18,194
somatic variants per tumor (3387–73,003), which was
highly similar to 259 MSS sCRCs previously whole-genome
sequenced in-house (median, 17,319; range, 253–84,646)
(Supplementary Figure 2); genome-wide mutation densities
showed similar distributions. Coding sequences displayed
4702 variants, with 2816 genes affected by nonsynonymous
variants. We ranked the 100 genes mutated in 3 or more
tumors by mutation density (Figure 1A). Top 20 genes
featured several known CRC driver genes, including TP53
and KRAS having the highest mutation densities. Analysis of
mutual exclusivity and co-occurrence of mutations in these
genes revealed no significant results (Supplementary
Table 1). As expected, KRAS and APC mutations were few
in IBD-CRCs compared to sCRCs (22% vs 49% and 22%
vs 73%, respectively, Fisher exact test, P ¼ .0087 and
P ¼ 2.5  107); TP53 was frequently mutated in both
groups (63% vs 62%) (Figure 1A, Supplementary Table 2).
A comparison of all variants in COSMIC Cancer Gene
Census51 genes revealed paucity of genes mutated uniquely
in IBD-CRC (Supplementary Table 2).
Immunity-related CARD8 and PIGR ranked high by mu-
tation density (Figure 1A). All 3 CARD8 variants were
missense, and 2 of the 4 PIGR variants present in 3 of 27
IBD-CRCs (11% vs 1% in MSS sCRCs) were truncating
(Supplementary Table 3).Noncoding TP53 Mutations Are Enriched in
Inflammatory Bowel Disease–Associated
Colorectal Cancers
To discover candidate driver genes, we applied Onco-
driveFML25 to all somatic point mutations from the 27 MSS
IBD-CRCs, totaling 622,366 variants. Coding regions of 2
genes showed significant evidence of positive selection
after false discovery rate (FDR) correction (Q < 0.1), TP53
(P < 1.1  10–6, Q ¼ .00061) mutated in 16 tumors and
GBA2 (P ¼ .00014, Q ¼ .043) mutated in 2 tumors
(Supplementary Figure 2, Supplementary Table 4). We
further analyzed 30UTR and 50UTR of all protein-coding
genes. Overlapping 50UTR of TP53 and WRAP53 genes was
the only region showing significant evidence of positive
selection (P ¼ .00036, Q ¼ .022) in IBD-CRCs, while
remaining nonsignificant in sCRCs (P ¼ .015, Q ¼ 1.00)
(Supplementary Figure 2, Supplementary Table 4). This
region harbored 4 mutations in 3/27 IBD-CRCs and 6 mu-
tations in 5 of 239 sCRCs, resulting in low TP53 expression
(Figure 1B and C).Uncoupling of Age-Related Mutational Signature
From Age in Inflammatory Bowel Disease–
Associated Colorectal Cancers
Detection of genome-wide mutational signatures22,24 in
IBD-CRCs revealed 5 somatic SBS signatures that resembled
the signatures SBS1 (age-related spontaneous deamination
of 5-methylcytosine), SBS8 (unknown), SBS17 (CTCF/cohesin binding sites), and SBS15 and SBS20 (defective DNA
mismatch repair) in human cancers described previ-
ously22,52 (Figure 2A). Compared to MSS sCRCs, MSS IBD-
CRCs showed a decreased exposure to SBS1 (P ¼ .0037)
(Figure 2B) and a significantly lower rate of SBS1 mutations
during life before CRC diagnosis (ordinary least squares,
P ¼ .023). Neither the mean difference nor difference in
SBS1 mutation rate could be explained in Bayesian analysis
by the younger age at onset in IBD-CRC patients (mean ±
SD, 54 ± 11 years vs 69 ± 11 years in IBD-CRC vs sCRC)
(Figure 2C). SBS17 exposure was elevated (P ¼ .0082) in
IBD-CRCs (Figure 2B); tumors dominated by SBS17 showed
no obvious correlations to clinical characteristics or known
driver mutations.Analysis of Chromosomal Rearrangements
Reveals Tumor Type–Specific Allelic Imbalance
Chromosomal stability of the MSS IBD-CRCs was
inspected using both nanopore WGS data (n ¼ 19) and
single nucleotide polymorphism array data (n ¼ 27).
Numbers of somatic nanopore-detected SVs did not
differ between IBD-CRCs and sCRCs (Mann-Whitney U test
P > .76) (Figure 3A–C). Coding region SVs in IBD-CRC
revealed 5 genes with a recurring somatic breakpoint:
CCSER1 (n ¼ 2 tumors), FHIT (n ¼ 2), IMMP2L (n ¼ 3),
MACROD2 (n ¼ 2), and PIBF1 (n ¼ 2) (Supplementary
Table 5), all known fragile site genes.53,54
We previously characterized AI in 1699 CRCs26 and now
compared MSS IBD-CRCs (n ¼ 27) to MSS sCRCs (n ¼ 1360).
No overall difference between IBD-CRCs (mean, 9.2  108
bp of AI per tumor) and sCRCs (mean, 1.1  109 bp) was
observed (Mann-Whitney U test P ¼ .29) (Figure 3D). The
only outstanding difference genome-wide (at FDR < 10%)
was found at 5p13.1-p12, where IBD-CRC was enriched for
gains (10 of 27 tumors (37%); Figure 3E; Supplementary
Table 6). Of the genes in this region, OSMR and LIFR cyto-
kine receptors sharing the ligand oncostatin M55 were
significantly up-regulated in IBD-CRCs compared to sCRCs
(Supplementary Table 7). Closer inspection of 38 previously
characterized AI target genes in CRC26 revealed 4 genes
with differential AI (FDR < 10%): CDKN2B and SMARCA2
enriched for allelic losses, FOXA1 for allelic gains, and
HNF4A having fewer gains in IBD-CRC compared to sCRC
(Supplementary Table 8).Differential Gene Expression Highlights Changes
Related to Stromal and Immune Cells in
Inflammatory Bowel Disease–Associated
Colorectal Cancers
Bulk RNA sequencing revealed 870 significantly differ-
entially expressed (DE) genes between MSS IBD-CRCs and
MSS sCRCs (FDR < 10%; Supplementary Table 7,
Supplementary Figure 3). In IBD-CRCs, pathway analysis
showed a strong overenrichment (overexpression) of gene
sets related to complement activation and extracellular
matrix organization (Figure 4A, Supplementary Table 9).
Very few gene sets were significantly underenriched,
Figure 1. Somatic point mutations. (A) OncoPrint (https://www.cbioportal.org/oncoprinter) showing somatic point mutations
(filled squares) and copy number alterations (filled bars) in genes mutated in 3 or more MSS IBD-CRCs and ranked by mutation
density (mutations/Mb; top 20 genes and APC ranking no. 41 presented with percentages of mutated tumors). F, female; IBD-
U, unclassified inflammatory bowel disease; M, male; TNM, tumor-nodes-metastases. (B) Variants observed in the overlapping
50UTR of TP53 and WRAP53. IRES, internal ribosome entry site. (C) Gene expression in 64 RNA-sequenced CRCs as tran-
scripts per million (TPM). Red dot signifies an IBD-CRC carrying TP53/WRAP53 50UTR variant (no coding TP53 variants).













ATincluding only 1 of 44 significant results for Reactome
database, TCF-dependent signaling in response to WNT (R-
HSA-201681). Genes in this set included RNF43 and AXIN2,
the most significantly down-regulated genes in IBD-CRCs.
The most significantly up-regulated gene, OSMR, appeared
in a large overenriched Immune System gene set (R-HSA-
168256) comprising 146 DE genes related to myeloid/lymphoid immune cells, complement, and, interestingly,
EMT (TWIST1, ZEB1, VIM) (Supplementary Table 9).
We estimated cell type–specific gene expression profiles
for epithelial, stromal, and immune cells using PRISM
deconvolution tool35 (Supplementary Figure 4). PRISM-
estimated cell-type proportions for each tumor consensus
molecular subtype (Supplementary Figure 5) matched those
Figure 2. Somatic mutational signatures. (A) Contributions of SBS signatures to somatic mutations in IBD-CRCs. CBS, CTCF/
cohesin binding site. (B) SBS signatures in IBD-CRCs (MSS n ¼ 25) and sCRCs (MSS n ¼ 194, MSI n ¼ 12). Robust linear
model regression was used to compare the MSS groups (**P < .01). (C) Analysis of age-dependence of SBS1. After Bayesian
analysis with and without intercept, depending on the IBD status, the slope for IBD-CRCs for SBS1 exposure is significantly
lower than for sCRCs. On average, the MSS IBD-CRCs had 7.4–61 fewer SBS1-associated mutations per year (95% credible
interval).




ATreported previously using a different algorithm.17 Differen-
tial expression analysis between MSS IBD-CRCs and MSS
sCRCs yielded 376, 626, and 66 DE genes for epithelial,
stromal, and immune cells, respectively (Supplementary
Table 7). Pathway analysis of these separate gene lists
allowed connecting each pathway change to a particular cell
type (Supplementary Table 9). Epithelial DE genes, pre-
dominantly down-regulated in IBD-CRCs, were enriched for
pathways related to epithelial cell differentiation and
development. Stromal DE genes, predominantly up-
regulated, were enriched for extracellular matrix organiza-
tion, integrin interactions, vasculature development, and
insulin-like growth factor metabolism. Immune DE genes,
predominantly up-regulated, were enriched for classical
complement activation and other antibody-mediated im-
mune responses.Common Epithelial Colorectal Cancer Subtype
Associated With WNT Signaling Is Absent in
Inflammatory Bowel Disease–Associated
Colorectal Cancers
We defined the nearest CMS for each of the 64 RNA-
sequenced CRCs, as described previously.17 As reported,
MSI sCRCs were highly enriched for CMS1 (Supplementary
Table 10). Based on PRISM deconvolution, immune cell
proportion was highest in CMS1, stromal in CMS4, and
epithelial in CMS2/CMS3 tumors (Supplementary Figure 5),
as reported previously.17 Comparison of MSS tumors in IBD-
CRCs revealed a striking paucity of the canonical epithelial
CMS2 subtype associated with WNT and MYC signaling (0%
of IBD-CRCs vs 39% of sCRCs; P ¼ .0048, Padj ¼ .019)
(Figure 4B, Supplementary Table 10). IBD-CRCs were
Figure 3. Overview of somatic structural aberrations. Numbers of somatic (A) intra- and (B) inter-chromosomal, and (C) total
SVs in 19 nanopore-sequenced MSS IBD-CRCs and 32 MSS sCRCs. The percentages in (B) refer to the proportion of tumors
lacking inter-chromosomal SVs. (D, E) Somatic AI in 27 MSS IBD-CRCs and 1360 MSS sCRCs across the autosomes. (D) Total
amount of base pairs affected by somatic AI. Dashed lines denote the mean per group (orange/blue) and overall mean (gray).
Y-axis is logarithmic and truncated to a minimum 100 kbp. (E) Observed proportion of tumors with allelic loss (or gain) at each
genomic position.













ATdominated by mesenchymal CMS4 (57% vs 21%; P ¼ .019,
Padj ¼ .057), with concomitant up-regulation of transcrip-
tion factors mediating EMT (TWIST1, TWIST2, SNAI2, ZEB1,
ZEB2) (Supplementary Table 7).Mesenchymal Tumors Show a Distinct Pattern of
Immune Cell Infiltration
We interrogated the immune cell contexture of RNA-
sequenced CRCs using CIBERSORT deconvolution.31,32 MSI
and CMS1 tumors were found in clusters with high esti-
mated proportions of CD8þ cytotoxic T cells
(Supplementary Figure 5), as reported previously.17 MSS
tumors showed 3 clusters dominated by CD4þ T, CD8þ T,
and B cells, respectively (Figure 4C). IBD-CRCs were divided
between the B cell and the CD4þ T cell clusters, forming in
the latter a distinct CMS4-enriched subcluster distinguished
by high proportions of monocytes.
We further analyzed immune cell score, a prognostic
measure of tumor T cell infiltration reflecting numbers of
total (CD3þ) and cytotoxic (CD8þ) T cells.41 Rates of high
immune cell score (3–4) were similar between 24 MSS IBD-
CRCs and 196 MSS sCRCs (54% vs 43%; Fisher exact test,
P ¼ .39) (Supplementary Table 11). There were no signifi-
cant differences in the 4 individual stainings (Figure 4D) or
in the ratios of CD8þ to CD3þ T cells (Supplementary
Figure 5) between these groups (Mann-Whitney U test,
Holm-Bonferroni correction).Similar Genome-Wide Methylation Patterns in
Inflammatory Bowel Disease–Associated
Colorectal Cancers and Sporadic Colorectal
Cancer
Methylation analyses were carried out using whole-
genome nanopore sequencing data. Based on methylation
values at CpG islands, IBD-CRCs and a pool of nondysplastic
normal colon samples from patients with IBD (“IBD-nor-
mals”) mainly clustered separately from sCRCs
(Supplementary Figure 6). All subsequent methylation an-
alyses focused on samples from patients with MSS tumors.
IBD-CRCs showed, on average, higher genome-wide
methylation compared to sCRCs (Figure 5A). Neither age
nor cancer type was significantly associated with the
average methylation level (joint model P ¼ .078). Differen-
tially methylated loci (DMLs) were studied in autosomes
comparing IBD-CRCs to IBD-normals and sCRCs to IBD-
normals, resulting in 553,390 DMLs (4.4% hyper-
methylated) and 2,413,663 DMLs (3.7% hypermethylated),
respectively. Five of the 10 IBD-normals were matched with
the studied IBD-CRCs, likely decreasing the IBD-CRC DML
count, potentially affected also by shared IBD-derived
methylation changes.
In both tumor groups, genomic annotation of the DMLs
(Figure 5B–D, Supplementary Figure 6) revealed the ma-
jority of hypomethylated loci at non-CpG island (“CpG in-
ter”) areas and modest enrichment only on quiescent/low
chromatin areas, out of 15 chromatin states studied.
Figure 4. Patterns of gene expression and immune cell infiltration. (A–C) RNA sequencing data from 14 MSS IBD-CRCs and 38
MSS sCRCs was compared. (A) Top 10 pathways significantly enriched among DE genes (n ¼ 870) in PANTHER Statistical
Enrichment Test30 against the Reactome database. (B) CMS17 presented as the nearest CMS having the highest posterior
probability (equal for CMS1 and CMS4 in one tumor). (C) Clustering of tumors based on the estimated proportions of immune
cells from CIBERSORT deconvolution. NK, natural killer. (D) CD3þ and CD8þ T cell numbers determined by immunohisto-
chemistry at the tumor core (tc) and invasive margin (im) in 25 MSS IBD-CRCs, 217 MSS sCRCs, and 20 MSI sCRCs.




ATConversely, most of the hypermethylated loci were located
on CpG islands and intronic areas (Figure 5B), showing
enrichment on several chromatin states related to bivalent
chromatin (Figure 5C). From chromatin states with average
odds ratio >20, the enrichment of hypermethylation rela-
tive to IBD-normals was lower in IBD-CRC compared tosCRC on bivalent/poised transcription start sites (TSS)
(Mann-Whitney U test, Padj < 1.6  10–6) and flanking
bivalent TSS/enhancers (Padj ¼ .00011). In both groups, the
enrichment of hypermethylated loci was strongest on
H3K27me3 marked chromatin (Figure 5D). We further
inspected whether the DE genes were commonly annotated
August 2021 Inflammatory Bowel Disease and Colon Cancer 601with bivalent TSS, which was indeed the case more often
than expected by chance (Supplementary Figure 7).HNF4A Binding Sites Are Hypomethylated Solely
in Sporadic Colorectal Cancer
We studied the enrichment of DMLs in chromatin
immunoprecipitation sequencing peaks of 382 transcription
factors and DNA binding proteins obtained from LoVo CRC
cell line.50 Significant enrichment was detected at multiple
binding sites in both tumor groups compared to IBD-
normals (Supplementary Table 13). However, the signifi-
cance often originated from a small total number of binding
sites harboring DMLs, diminishing the biologic relevance,
especially in results unique to IBD-CRCs. In sCRCs, the most
significant enrichment of hypomethylation relative to IBD-
normals was found at HNF4A binding sites, with DMLs
detected at >3000 separate binding sites. This enrichment
was absent in IBD-CRCs, in agreement with fewer HNF4A
gains. As reported previously,17 the frequency of HNF4A
gains and HNF4A expression, together with APC mutations,
were highest in CMS2 tumors (Supplementary Figure 8).
Interestingly, binding sites of TCF7L2, key transcription
factor mediating WNT/b-catenin signaling, showed hypo-
methylation only in sCRC when compared to IBD-normals,
and binding sites of MYC, a critical WNT/b-catenin target
gene, were enriched for hypermethylation in IBD-CRCs












ATPIGR and OSMR Involved in Mucosal Immunity
Show Dysregulated Promoter Methylation in
Inflammatory Bowel Disease–Associated
Colorectal Cancers
We next identified genes containing DMLs at promoter
region (1 kbp upstream of TSS) in IBD-CRCs, but not sCRCs,
compared to IBD-normals. Thirteen and 7 protein coding
genes contained >1 hyper- or hypomethylated loci,
respectively, at their promoter. Visualization of methylation
patterns around these transcripts, together with their
expression data (Supplementary Figure 9) revealed
distinctly high PIGR promoter methylation in IBD-CRCs, with
significantly reduced epithelial expression (Figure 6A and B;
Supplementary Table 7; Supplementary Figure 10). An IBD-
CRC harboring 2 somatic PIGR mutations displayed lower
methylation values than IBD-CRCs with wild-type PIGR
(n ¼ 18) (Figure 6A).
DML calling and annotation comparing the 2 tumor
groups (Supplementary Figures 11 and 12) revealed mul-
tiple hypomethylated DMLs at OSMR promoter region in
IBD-CRCs compared to sCRCs (Figure 6C, Supplementary
Figures 10 and 12). Stromal OSMR expression was
strongly elevated in IBD-CRCs and particularly high in CMS4
tumors (Figure 6D), showing a strong correlation with
expression of EMT-related genes especially in IBD-CRCs
(Supplementary Figure 13). Inspection of protein coding
genes having DMLs at gene bodies (exons, introns, and 50/
30UTRs) revealed enrichment of WNT pathway genes for
gene body hypermethylation in IBD-CRC compared to sCRC(Supplementary Table 14), including AXIN2 and RNF43
strongly down-regulated in IBD-CRCs (Supplementary
Table 15, Supplementary Table 7).Discussion
Increased risk of CRC in IBD patients has been attributed
to long-standing chronic inflammation, yet the underlying
mechanisms remain poorly understood.3,4 Here, we inte-
grated data from multiple experimental approaches to gain
a deeper understanding of IBD-CRC. While many tumor
characteristics, including somatic AI, SVs, and genome-wide
methylation patterns, showed an overall similarity to sCRCs,
several distinct features were identified, as summarized in
Supplementary Table 17.
Constitutive activation of WNT/b-catenin signaling via
loss-of-function mutations in APC is a hallmark of sCRC.4
The pathway regulates cell fate, proliferation, polarity, and
stemness via b-catenin–dependent and –independent
mechanisms.56 The most common transcriptomic CRC sub-
type, CMS2, displays up-regulation of WNT and MYC target
genes and an epithelial differentiation signature.17 Among
our MSS sCRCs, 39% were CMS2. In striking contrast, CMS2
was completely absent among IBD-CRCs, dominated instead
by mesenchymal CMS4 previously associated with EMT,
matrix remodeling, transforming growth factor b (TGF-b)
signaling, complement activation, and depletion of WNT/
MYC-related expression signatures.17 Differential expres-
sion analysis reflected this CMS2 vs CMS4 predominance,
revealing in IBD-CRCs enrichment of gene sets involved in
extracellular matrix organization and complement activa-
tion, up-regulation of key transcription factors mediating
EMT, and down-regulation of genes related to epithelial
differentiation. Moreover, binding sites of TCF7L2 and MYC,
mediators of canonical WNT signaling, were hypomethy-
lated in sCRCs relative to IBD-CRCs. Thus, an alternative
mode of WNT dysregulation may govern tumorigenesis in
IBD-CRCs that still show accumulation of nuclear/cyto-
plasmic b-catenin.11
EMT involves loss of tumor cell polarity and cell–cell
adhesion to gain more migratory and invasive proper-
ties.57 WNT signaling is a prominent regulator of EMT in
CRC57 and could thus contribute to the observed mesen-
chymal skewing of IBD-CRCs. One mechanism could involve
the differential activity of HNF4a transcription factor,
essential for embryonic development of colonic epithe-
lium.58 We showed that HNF4a binding sites were highly
significantly hypomethylated in sCRCs but not in IBD-CRCs,
implying increased binding in sCRC tumorigenesis. Chro-
mosomal gains at HNF4A locus were more common in
sCRCs, enriching in CMS2 tumors. In hepatocellular carci-
noma, HNF4a maintains epithelial tumor phenotype by
facilitating corepression of EMT-related WNT/b-catenin
target genes,59 putting a break on EMT. HNF4A gains could
enforce this mechanism in sCRCs with constitutive WNT/b-
catenin activation, promoting the establishment of epithelial
CMS2 tumors. Conversely, in a mouse model of colitis,
inflammation-induced epigenetic change resulted in
reduced HNF4a occupancy.60 Thus, a state of low HNF4a





Figure 6. Patterns of PIGR and OSMR methylation and expression. (A) Smoothing of the methylation measurements around
PIGR from 18 PIGR wild-type vs 1 PIGR-mutated IBD-CRC, 32 PIGR wild-type sCRCs, and 10 IBD-normals. (B) Deconvoluted
PIGR expression data; data from epithelial cells are plotted against tumor-node-metastases (TNM) stage and CMS. (C)
Smoothing of the OSMR methylation data. (D) Deconvoluted OSMR expression data; data from stromal cells are plotted
against TNM stage and CMS.
=
Figure 5.Genome-wide annotation of methylation patterns. (A) Average genome-wide methylation levels from 19 MSS
IBD-CRCs, 32 MSS sCRCs, and 10 nondysplastic normal colon tissue samples from IBD patients. (B) Proportion of hyper-
methylated DMLs in tumors compared to IBD normals at different genomic regions. (C, D) Enrichment analysis of hyper-
methylated loci using Roadmap Epigenomics chromatin annotations from tissue samples of the normal human gastrointestinal
tract and samples relevant to tumorigenesis. Different colors depict different tissue origins of the cells (Supplementary
Table 12).


















AToccupancy may pre-exist in patients with IBD. Once
tumorigenesis is set forth by TP53 mutations and aberrant
WNT signaling, it may favor the emergence of mesenchymal
CMS4 tumors through EMT from the earliest stages of
tumorigenesis.
The paucity of APC and KRAS mutations in IBD-CRC has
been identified consistently.4,6–10 Novel driver mutations
explaining the relative independence of IBD-CRC from these
key sCRC driver events have not emerged. We revealed
evidence for positive selection of somatic mutations at
noncoding 50UTR of TP53 in IBD-CRCs, resulting in low TP53
expression. A recent pan-cancer analysis described similar
variants in this region as a novel rare driver event reducing
TP53 expression,61 further highlighting the importance of
TP53 loss in IBD-CRC.4 We could not identify a distinct
subgroup of MSS IBD-CRCs with elevated genome-wide
mutation densities, as suggested earlier by panel
sequencing.62
Two negative feedback regulators induced by WNT
signaling, AXIN2 and RNF43, were strongly down-regulated
in IBD-CRCs compared to sCRCs. AXIN2 participates with
APC in the b-catenin destruction complex,63 while RNF43
inhibits upstream WNT signaling by inducing the degrada-
tion of frizzled receptors.64 Both genes are commonly
mutated in MSI sCRCs showing mutual exclusivity with APC
mutations63,65 and down-regulated in APC wild-type
compared to APC-mutated MSS sCRCs.66,67 Thus, loss of
WNT regulation by AXIN2 and RNF43 could trigger aberrant
WNT signaling in APC wild-type CRCs enriched among MSI-
CRCs and IBD-CRCs. Moreover, disruption of AXIN2 and
RNF43 in serrated adenomas and carcinomas66,68,69 may
link them with nonconventional types of precursor lesions
common in IBD-CRC.4 Intriguingly, model organoids
mimicking sessile serrated adenomas, but not conventional
tubular adenomas, are responsive to TGF-b–induced devel-
opment toward CMS4.70
Tumor immune cell infiltrate in CMS4 IBD-CRCs was
dominated by CD4þ T cells and monocytes. In agreement,
CMS4 has been linked with an “immune inflamed” immu-
nosuppressive microenvironment enriched in CD4þ regu-
latory T cells and monocyte-derived macrophages.71 The
remaining IBD-CRCs were dominated by B-cell infiltration.
While the role of B lymphocytes in cancer remains poorly
understood, this could result from an attempt to compen-
sate for reduced PIGR expression and disrupted epithelial
transport of B cell–derived IgA.
IBD-CRCs tended to show higher genome-wide methyl-
ation compared to sCRCs, but decreased exposure to
mutational signature linked with age-driven deamination of
5’methylcytosines; the latter was found also when
compared with tumors from patients with Lynch syn-
drome.62 Neither were explained by the younger age at
diagnosis or by differential expression of DNMT or TET
enzymes regulating DNA methylation, suggesting
inflammation-driven methylation changes.
Aberrant methylation patterns were detected in 2 genes
related to mucosal immunity solely in IBD-CRCs. PIGR me-
diates IgA and IgM transport across intestinal epithelium72and accumulates somatic loss-of-function mutations in
IBD-affected colon.73–75 PIGR showed promoter hyper-
methylation in IBD-CRCs compared to IBD-affected non-
dysplastic colon, with down-regulated expression. This may
imply further selection for PIGR loss during tumorigenesis,
which could promote epithelial barrier dysfunction and
sustained inflammation.72 Alternatively, the progressive loss
of PIGR with increasing tumor stage could reflect gradual
loss of epithelial properties in tumor cells. OSMR, encoding a
receptor for cytokine oncostatin M (OSM), showed promoter
hypomethylation, frequent chromosomal gain, and strong
overexpression in IBD-CRCs. Deconvolution analysis pointed
toward OSMR overexpression originating from stromal cells.
In agreement, OSMR-positive inflammatory stromal cells
expand in IBD-affected colon.76 Importantly, elevated in-
testinal OSMR and OSM expression is associated with a
subgroup of IBD patients showing poor response to TNFa
blockers.76 As OSM stimulation triggers EMT and mesen-
chymal characteristics in breast cancer cells,77 increased
OSM-OSMR signaling in IBD could favor the establishment of
mesenchymal CRC subtype, although this remains to be
studied further.
Our study represents one of the largest next-generation
sequencing datasets on both IBD-CRC and sCRC patients
published so far. Multiple data layers allowed deep char-
acterization of these tumors. Even larger studies would be
needed to control for more detailed clinical parameters,
such as UC/CD differences, changes in anti-inflammatory
medication for IBD over time, and different patient popu-
lation backgrounds. Further limitations include lack of non-
IBD normal colon in methylation analyses, and potential
batch effects. The rich layers of data created, focus on re-
sults showing connections between different data sets, and
rigorous batch-to-batch quality control mitigate many of
these effects. For methylation analyses, IBD-CRCs were
compared with both IBD normal colon and sCRCs to better
capture differences distinguishing IBD-associated
tumorigenesis.
Taken together, our results highlight skewing of IBD-
associated tumorigenesis toward increased importance of
the dynamic process of EMT, driven by distinct mechanisms
of WNT pathway dysregulation compared to sCRC. The
mesenchymal tumor subtype enriched in IBD-CRCs has been
associated with drug resistance18 and worse relapse-free
and overall survival in large CRC patient cohorts,17 which
may affect prognosis and treatment options in IBD-CRC.
OSM-OSMR signaling could contribute to establishment of
this mesenchymal subtype in IBD patients, potentially
linking a TNFa blocker–resistant subgroup of patients with
increased CRC risk. Cost-effective and clinically feasible al-
ternatives for CMS subtyping, including immunohisto-
chemistry, are reaching high accuracy.18 First treatment
combinations targeted toward CMS4-like TGF-b–activated
CRC have entered clinical trials,18 paving the way for
overcoming the tumor-microenvironment crosstalk that
drives the mesenchymal phenotype. Further studies are
needed to determine whether similar approaches are
beneficial in treatment of IBD-CRC.
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